Results 11 to 20 of about 687 (125)
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection. [PDF]
PLoS ONE, 2015 Dimethyl fumarate is an immunomodulatory and neuroprotective drug, approved recently for the treatment of relapsing-remitting multiple sclerosis. In view of the limited therapeutic options for human acute and chronic polyneuritis, we used the animal ...
Kalliopi Pitarokoili +4 more
doaj +1 more source
Neurobiology of Disease, 2015 Background and purpose: Edema formation, inflammation and increased blood–brain barrier permeability contribute to poor outcomes after intracerebral hemorrhage (ICH).
Loretta O. Iniaghe +5 more
doaj +1 more source
Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis [PDF]
Farmacia Hospitalaria, 2021 Objective: Dimethyl fumarate is a medication approved for the treatment of relapsing-remitting multiple sclerosis. The purpose of the study was to evaluate the safety and persistence of dimethyl fumarate in clinical practice and analyze the ...
Silvia Boullosa-Lale +3 more
doaj +1 more source
Frontiers in Medicine, 2022 Psoriasis vulgaris is a chronic inflammatory skin disease characterized by well-demarcated scaly plaques. Oxidative stress plays a crucial role in the psoriasis pathogenesis and is associated with the disease severity.
Elena Campione +16 more
doaj +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019 Background The use of dimethyl fumarate has not been reported in treatment-naïve Japanese patients with relapsing–remitting multiple sclerosis. Objectives The purpose of this study was to evaluate the efficacy and safety of dimethyl fumarate in treatment-
Masahiro Mori +7 more
doaj +1 more source
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. [PDF]
PLoS ONE, 2016 The paper aimed to estimate the incremental cost-effectiveness ratio (ICER) at the public published price for delayed-release dimethyl fumarate versus relevant Multiple Sclerosis disease-modifying therapies available in France in June 2015.The economic ...
Julie Chevalier +3 more
doaj +1 more source
Drug-Repurposing Strategy for Dimethyl Fumarate
Pharmaceuticals, 2023 In the area of drug discovery, repurposing strategies represent an approach to discover new uses of approved drugs besides their original indications.
Salvatore Giunta +8 more
doaj +1 more source
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes
Redox Biology, 2015 Oxidative stress contributes to pathology associated with inflammatory brain disorders and therapies that upregulate antioxidant pathways may be neuroprotective in diseases such as multiple sclerosis.
He Huang +2 more
doaj +1 more source
A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models
Frontiers in Molecular Biosciences, 2022 Friedreich’s ataxia (FA) is an inherited multisystemic neuro- and cardio-degenerative disorder. Seventy-four clinical trials are listed for FA (including past and present), but none are considered FDA/EMA-approved therapy.
Rosella Abeti +7 more
doaj +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018 Background Dimethyl fumarate is an oral treatment for multiple sclerosis, whose mechanism of action is not fully understood. Objective To investigate the effects of dimethyl fumarate on DNA methylation in the CD4 + T cells of multiple sclerosis patients.
Vicki E Maltby +7 more
doaj +1 more source